Should Finasteride Be Discontinued After TURP?
Yes, finasteride should generally be discontinued after successful TURP once normal voiding is confirmed, as the primary indication for its use—treating symptomatic BPH with an enlarged prostate—has been surgically addressed.
Rationale Based on FDA-Approved Indications
The FDA label clearly states that finasteride is indicated for treating symptomatic BPH to improve symptoms, reduce acute urinary retention risk, and reduce the need for surgery including TURP 1. Once TURP has been performed and the obstructing prostatic tissue removed, the original indication for finasteride therapy no longer exists 1.
Evidence on Post-TURP Medication Use
Current Practice Patterns Show Overuse
Research demonstrates that 20-28% of patients continue 5α-reductase inhibitors (5ARIs) after TURP despite lack of evidence supporting this practice 2, 3. A large Canadian study of 58,038 men found that 32% used 5ARIs before TURP, but 20% continued them afterward, with a cumulative 10-year probability of 28% 3. The authors explicitly state there is "considerable use of AB and 5ARIs despite a lack of evidence for using these medications after a TURP" 3.
Limited Evidence for Continuation
The only scenario where continuing 5ARIs post-TURP shows benefit is in patients with very large prostates (>80 mL) who had incomplete resection 4. In this specific population, continuing 5ARIs for 3 years improved prostate volume, PSA, maximum flow rate, and hematuria 4. However, this represents a minority of TURP patients and assumes significant residual prostatic tissue remains.
Clinical Decision Algorithm
Discontinue finasteride if:
- TURP successfully removed obstructing tissue
- Patient achieves normal voiding without catheter
- Post-void residual is acceptable
- Symptoms are adequately controlled
- Standard post-TURP recovery is occurring
Consider continuation only if:
- Residual prostate volume remains >80 mL after incomplete resection 4
- Persistent hematuria from residual vascular prostatic tissue (though evidence is limited) 5
- Patient has documented recurrent prostatic regrowth on imaging
Important Caveats
Perioperative Use Is Different
The AUA guideline notes that 5ARIs may reduce intraoperative bleeding during TURP 6, but this refers to preoperative use (typically weeks before surgery), not continuation after surgery.
Mechanism No Longer Relevant
Finasteride works by shrinking prostatic tissue through DHT reduction, achieving 15-25% volume reduction over 6 months 6. After TURP mechanically removes the obstructing tissue, this pharmacologic mechanism becomes redundant for the primary indication 6, 1.
Avoid Unnecessary Side Effects
Continuing finasteride exposes patients to ongoing risks of sexual dysfunction, gynecomastia, and potential post-finasteride syndrome without clear benefit 6. Discontinuation eliminates these risks once the surgical goal is achieved.
Common Pitfall
The high rates of post-TURP 5ARI use (20-28%) 2, 3 likely reflect prescriber inertia rather than evidence-based practice. Do not continue medications simply because they were started preoperatively—reassess the indication post-procedure.